Eurofins stock holds steady as investors eye recent revenue growth

Eurofins Scientific stock (ISIN FR0014000MR3) is trading steadily as of September 6, 2026, with investors looking closely at the companys multi-billion euro revenue base and its role as a global leader in laboratory testing services.

Revenue scale underpins Eurofins valuation

Eurofins Scientific has highlighted that it generated total revenues of about EUR 6.7 billion in fiscal year 2024, confirming the scale of its global testing and laboratory network according to a recent corporate job posting for positions in Ottawa, Canada.The posting notes that Eurofins generated total revenues of EUR 6.7 billion in 2024.

While detailed quarterly figures for 2026 are not yet visible in the latest search snapshot, the 2024 revenue level serves as a historical reference point that helps investors gauge the companys earnings power. Historically, the companys growth has been supported by strong demand for testing services in pharmaceuticals, food safety, environmental analysis and consumer products, which has translated into multi-billion euro top line figures.

Market performance and investor perspective

Eurofins stock is listed in Paris with the ISIN FR0014000MR3, and the shares are also available to German investors via secondary trading on local platforms that track the security under the German code A2QJCT.A German stock portal shows Eurofins Scientific trading under the identifier A2QJCT and ISIN FR0014000MR3.

According to this German stock overview as of early September 2026, Eurofins Scientific shares have displayed a mixed performance over longer periods, with multi-year gains reflecting the companys status as one of Europes better performing stocks over the past two decades, contrasted by shorter-term fluctuations tied to sector sentiment.A corporate overview notes that Eurofins has been among the best performing stocks in Europe over the past 20 years.

Testing services as a revenue driver

A key pillar of Eurofins Scientifics business model is laboratory testing for biopharmaceutical companies, medical devices and consumer products, which generates recurring revenue streams from clients that must comply with regulatory and quality standards.Eurofins Medical Device Services underlines the companys role in safety and performance testing for medical technology.

The companys scale in areas such as biopharma, food safety and consumer product testing has helped it reach the previously mentioned EUR 6.7 billion revenue level in 2024, and investors now watch closely how this base can grow further as new services and geographies are added.

Stock remains supported by long-term growth story

For shareholders, the attraction of Eurofins stock lies less in short-term price swings and more in the companys ability to sustain revenue growth from a diversified portfolio of testing services. The historical performance references that Eurofins has been one of Europes better performing stocks over the past twenty years reflect that the market has long rewarded this growth model.A corporate profile summarises Eurofins long-term stock performance in Europe.

As of September 6, 2026, investors will look for the next set of quarterly or half-year figures to confirm whether the company can build further on the 2024 revenue base and how margins and cash flow evolve alongside that topline.